From the Triumvirate to the Ominous Octet : A New Paradigm for the Treatment of Type 2 Diabetes Mellitus von DEFRONZO, Ralph A

Volltext

Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents von Di Pino, Antonino, DeFronzo, Ralph A

Volltext

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes von Ferrannini, Ele, DeFronzo, Ralph A

Volltext

Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study von Gastaldelli, Amalia, Gaggini, Melania, DeFronzo, Ralph A

Volltext

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes von DeFronzo, Ralph A, Tripathy, Devjit

Volltext

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition von DeFronzo, Ralph A., Norton, Luke, Abdul-Ghani, Muhammad

Volltext

Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes von Defronzo, Ralph A

Volltext

Insulin: The master regulator of glucose metabolism von Norton, Luke, Shannon, Chris, Gastaldelli, Amalia, DeFronzo, Ralph A.

Volltext

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors von DeFronzo, Ralph A., Reeves, W. Brian, Awad, Alaa S.

Volltext

Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose von DeFronzo, Ralph A., MD, Abdul-Ghani, Muhammad, MD, PhD

Volltext

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study von Abdul-Ghani, Muhammad, Del Prato, Stefano, Chilton, Robert, DeFronzo, Ralph A

Volltext

Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance von Gastaldelli, Amalia, Abdul Ghani, Muhammad, DeFronzo, Ralph A

Volltext

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes von DeFronzo, Ralph A, Inzucchi, Silvio, Abdul-Ghani, Muhammad, Nissen, Steven E

Volltext

Reduced time points to calculate the composite index von DeFronzo, Ralph A, Matsuda, Masafumi

Volltext

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30―50% of Filtered Glucose Load in Humans von ABDUL-GHANI, Muhammad A, DEFRONZO, Ralph A, NORTON, Luke

Volltext

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease von Gaggini, Melania, Morelli, Mariangela, Buzzigoli, Emma, DeFronzo, Ralph A, Bugianesi, Elisabetta, Gastaldelli, Amalia

Volltext

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes von Abdul-Ghani, Muhammad A, Norton, Luke, DeFronzo, Ralph A

Volltext

Pathogenesis of Insulin Resistance in Skeletal Muscle von Abdul-Ghani, Muhammad A., DeFronzo, Ralph A.

Volltext

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes von Muscogiuri, Giovanna, DeFronzo, Ralph A, Gastaldelli, Amalia, Holst, Jens J

Volltext

Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus von Abdul-Ghani, Muhammad A, Norton, Luke, DeFronzo, Ralph A

Volltext